Harry Cassin
Publisher and Editor
Andy Spalding
Senior Editor
Jessica Tillipman
Senior Editor
Bill Steinman
Senior Editor
Richard L. Cassin
Editor at Large
Elizabeth K. Spahn
Editor Emeritus
Cody Worthington
Contributing Editor
Julie DiMauro
Contributing Editor
Thomas Fox
Contributing Editor
Marc Alain Bohn
Contributing Editor
Bill Waite
Contributing Editor
Shruti J. Shah
Contributing Editor
Russell A. Stamets
Contributing Editor
Richard Bistrong
Contributing Editor
Eric Carlson
Contributing Editor
Shire Pharmaceuticals LLC will pay $56 million to settle allegations that its marketing and promotion of several drugs violated the False Claims Act, the Justice Department said Wednesday.
Jessica Tillipman and I co-teach the George Washington University Law School anti-corruption seminar in which the D.C. Metro enforcement action she wrote about will likely be a case study. I thought I would weigh in to offer some additional background information.
Tantalum, courtesy of Enough Project via YouTubeThe federal appeals court for the D.C. circuit issued its opinion Monday in National Association of Manufacturers (NAM), et al., v. Securities and Exchange Commission that partially struck down the SEC’s conflict minerals disclosure rule.
How many corporate enforcement actions since 2005 didn’t involve criminal or civil charges against any employees from the company? We find out.
For a variety of reasons, requiring training of agents and other third-party business representatives is among the most challenging aspects of having an anti-corruption compliance program. And, it is a challenge that apparently many companies have yet to address.
Here’s a chilling warning to company lawyers who may become involved in FCPA investigations.
We’re searching for clues about how enforcement decisions are made, and whether corporate settlements might be replacing individual prosecutions. Now we’ve got some numbers to help in the search.
Law firm Hughes Hubbard & Reed, a sponsor of the FCPA Blog, has released its FCPA/Anti-Bribery Mid-Year Alert 2010. The authors say it’s both a quick desk reference and — at 241 pages — an authoritative collection of FCPA resources. They’re right. There’s exhaustive enforcement-related information — DOJ and SEC actions, DOJ opinion procedure releases, […]
Health care giant Johnson & Johnson will pay more than $2.2 billion to resolve criminal and civil claims arising from allegations of kickbacks to U.S. doctors and improper marketing claims about three of its prescription drugs.
